XTL BIOPHARMACEUTICALS LTD
XTLB · XNASCIK 1023549fmd_01MM8YAVH9KVB307KW0P7D503F制造业 · 医药制剂模板: 标准
覆盖范围: 2015年1月01日 至 2025年12月31日，共 14 个期间
| 项目 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | – | – | – | – | – | 0 |
| 营业成本 | – | – | – | – | – | – | – | – | – | 0 |
| 毛利润 | – | – | – | – | – | – | – | – | – | 0 |
| 研发费用 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | – | – | 2 |
| 营业利润 | (4) | (3) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) |
| 利息费用 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 2 | – | 0 |
| 税前利润 | – | – | – | – | – | – | – | (1) | (2) | (1) |
| 所得税费用 | – | – | – | – | – | – | – | – | – | (0) |
| 持续经营净利润 | (4) | (3) | (1) | – | – | – | – | – | – | (1) |
| 净利润 | 0 | (3) | (1) | 4 | (1) | (3) | 0 | (1) | (2) | (1) |